aTyr Pharma (ATYR) investor relations material

Executive summary

• Report covers the quarter ended March 31, 2026, for a clinical-stage biotech focused on tRNA synthetase biology for fibrosis and inflammation therapies.

• Lead candidate efzofitimod is in development for interstitial lung disease (ILD), with ongoing and planned Phase 2 and Phase 3 studies, including pulmonary sarcoidosis and SSc-ILD.

• Plans to advance efzofitimod in pulmonary sarcoidosis after FDA Type C meeting, with IND submission for Phase 3 in June 2026.

• The company received notice of termination of its collaboration with Kyorin for efzofitimod in Japan, reverting global rights to the company.

• Poster on ATYR0101 accepted for presentation, highlighting preclinical anti-fibrotic activity.

Financial highlights

• Cash, cash equivalents, restricted cash, and available-for-sale investments totaled $68.3 million as of March 31, 2026.

• Net loss for Q1 2026 was $10.8 million, or $(0.11) per share, compared to $14.9 million in Q1 2025.

• Research and development expenses were $7.3 million for Q1 2026, mainly for clinical studies and preclinical candidates.

• General and administrative expenses were $4.1 million for Q1 2026.

• Cash and investments decreased from $80.9 million at year-end 2025 to $68.3 million at March 31, 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations for at least one year from the filing date.

• IND for Phase 3 efzofitimod in pulmonary sarcoidosis to be filed in June 2026, targeting up to 372 patients.

• EFZO-CONNECT Phase 2 study in SSc-ILD expected to complete enrollment in H1 2026.

• Additional capital will be required to fund planned Phase 3 trials and future operations; funding may come from equity, partnerships, or licensing.